Ionis Pharmaceuticals, Inc. develops and commercializes RNA-targeted therapies for serious diseases, focusing on neurology and cardiology. The company has created six marketed medicines, including treatments for genetic conditions such as amyotrophic lateral sclerosis (ALS). Ionis operates as a fully integrated biotechnology company, independently launching its products while also collaborating with partners on additional therapeutic programs. Its subsidiary, Akcea Therapeutics, commercializes specific RNA-targeted therapies in select markets.
